

# WHO Preferred Product Characteristics (PPC) for Malaria Vaccines


DEPARTMENT OF IMMUNIZATION,  
VACCINES AND BIOLOGICALS

Family, Women's and Children's Health (FWC)



**World Health  
Organization**





# **WHO Preferred Product Characteristics (PPC) for Malaria Vaccines**



---

**The Department of Immunization, Vaccines and Biologicals  
thanks the donors whose unspecified financial support  
has made the production of this document possible.**

This document was produced by the  
*Initiative for Vaccine Research (IVR)*  
of the Department of Immunization, Vaccines and Biologicals

*Ordering code: WHO/IVB/14.09*  
*Published: November 2014*

**This publication is available on the Internet at:**  
[www.who.int/vaccines-documents/](http://www.who.int/vaccines-documents/)

**Copies of this document as well as additional materials on  
immunization, vaccines and biologicals may be requested from:**

World Health Organization  
Department of Immunization, Vaccines and Biologicals  
CH-1211 Geneva 27, Switzerland  
• Fax: + 41 22 791 4227 • Email: [vaccines@who.int](mailto:vaccines@who.int) •

© World Health Organization 2014

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: [permissions@who.int](mailto:permissions@who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

**Printed by the WHO Document Production Services, Geneva, Switzerland**

---

# Contents

<b>1. Background and purpose .....</b>	<b>1</b>
1.1 <i>Target audience for WHO PPCs.....</i>	2
1.2 <i>Malaria Vaccines, A Strategic Priority for WHO.....</i>	2
1.3 <i>Context of available WHO recommended malaria interventions .....</i>	3
<b>2. Vaccines preventing malaria disease .....</b>	<b>4</b>
2.1 <i>Target Groups and Immunization Strategies .....</i>	4
2.2 <i>Endpoints and case definitions for evaluating disease-reducing         malaria vaccines .....</i>	6
2.3 <i>Trial design considerations for second generation malaria vaccines.....</i>	7
<b>3. Vaccines to reduce and interrupt malaria transmission .....</b>	<b>10</b>
3.1 <i>Transmission reducing malaria vaccines: target groups and         immunization strategies .....</i>	10
3.2 <i>Malaria transmission and endpoints for vaccine evaluation.....</i>	11
3.3 <i>Clinical Development considerations .....</i>	12
<b>4. WHO Prequalification .....</b>	<b>15</b>
<b>5. Malaria Vaccine Preferred Product Characteristics .....</b>	<b>16</b>
<b>6. Considerations on Programmatic suitability.....</b>	<b>20</b>

---

---

# 1. Background and purpose

Preferred product characteristics (PPCs) describe WHO preferences for parameters of vaccines, in particular its indications, target groups, possible immunization strategies, and features of clinical data desired related to safety and efficacy. These preferences are shaped by the unmet public health need in a priority disease area for which WHO encourages vaccine development. In keeping with its mandate, WHO preferences reflect its desire to promote the development of vaccines with high public health impact and suitable for use in low to middle-income countries.

PPCs are meant to provide early guidance for the development of new products or the improvement of existing ones. Each PPC addresses early stage vaccine R&D generally at least 5-10 years from vaccine availability, and will be reviewed and updated if necessary at least every 5 years. PPC are not static exit criteria, but are structured in such a way so as to drive innovation towards meeting public health needs.

Although the parameters in PPCs are commonly found in another product development tool often developed by industry known as target product profile (TPP), PPCs provide guidance tailored with the public health perspective. As the name suggests, PPCs focus on the preferred characteristics, while industry TPPs often specify minimally acceptable in addition to preferred criteria.

PPCs do not provide new guidance on other characteristics often described in TPPs such as vaccine presentation, packaging, thermostability, formulation and disposal, as this area is well-addressed by existing WHO processes such as the WHO Vaccine Presentation and Packaging Advisory Group (VPPAG) and the WHO Prequalification (PQ) process. The VPPAG interacts with manufacturers on questions related to presentation and packaging and has developed a preferred product profile on these aspects. (<http://www.who.int/immunization/policy/committees/vppag/en/index2.html>)

The WHO PQ process which assesses vaccine quality, safety, efficacy and suitability for use in low and middle-income countries has developed criteria called Programmatic Suitability for Prequalification (PSPQ) criteria to review vaccines submitted for prequalification. ([http://apps.who.int/iris/bitstream/10665/76537/1/WHO\\_IVB\\_12.10\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/76537/1/WHO_IVB_12.10_eng.pdf))

---

In addition to the documents related to PSPQ and VPPAG referred to above, malaria vaccine developers should be familiar with “Guidelines on the quality, safety and efficacy of recombinant malaria vaccines targeting the pre-erythrocytic and blood stages of *Plasmodium falciparum*”<sup>1</sup>.

Thus WHO encourages developers to consult the above links, in addition to the PPCs for guidance covering many aspects of TPPs, particularly if they intend to seek WHO Policy Recommendation and Prequalification for their products.

## 1.1 Target audience for WHO PPCs

The primary target audience is any entity intending to eventually seek WHO policy recommendation and prequalification for their products. Knowledge of WHO preferences can be useful to all those involved in malaria vaccine development, including academic groups from pre-clinical development onwards.

The PPCs are intended to encourage innovation and the development of vaccines that perform in settings most relevant to the global unmet public health need. At the same time, changes in scientific and technological feasibility could affect the PPCs. Each PPC document will be reviewed and, where necessary, revised at least every 5 years. In addition, changes to the Malaria Vaccine Technology Roadmap Strategic Goals may prompt revision of WHO PPCs for malaria vaccines. It is important to note that if a vaccine does not meet the PPC criteria, it could still be assessed by WHO for possible policy recommendations in the standard way.

## 1.2 Malaria Vaccines, A Strategic Priority for WHO

Malaria vaccine PPCs are aligned to the strategic priorities of WHO and partners as articulated by the two updated Malaria Vaccine Technology Roadmap goals<sup>2</sup>. The geographical distribution and burden of disease of *Plasmodium falciparum* and *Plasmodium vivax* malaria make these two pathogens high priority targets for vaccine development. In 2013, WHO’s principal advisory group on immunization, SAGE (Strategic Advisory Group of Experts) stated that “malaria vaccine development remains a global public health imperative”. The changing epidemiology of malaria and the call for eradication of the malaria parasite as a public health goal in recent years has led the global malaria vaccine community, in 2013, to update the *Malaria Vaccine Technology Roadmap*, which provides a blueprint for developing malaria vaccines. The current update calls for the development of vaccines targeting *Plasmodium falciparum* and *Plasmodium vivax*, by 2030 that address two unmet priority public health goals:

- Roadmap strategic goal 1: Malaria vaccines with a protective efficacy of at least 75% against clinical malaria, suitable for administration to appropriate at-risk groups in malaria-endemic areas<sup>3</sup>.

---

<sup>1</sup> [http://who.int/entity/biologicals/vaccines/Malaria\\_Guidelines\\_TRS\\_980\\_Annex\\_3.pdf](http://who.int/entity/biologicals/vaccines/Malaria_Guidelines_TRS_980_Annex_3.pdf).

This document is part of a class of documents known as WHO written standards used by National Regulatory Authorities to guide assessment of dossiers for licensure of vaccines. Written standards are also used by the WHO Prequalification team to guide PQ assessments of vaccines.

<sup>2</sup> [http://www.who.int/immunization/topics/malaria/vaccine\\_roadmap/en/](http://www.who.int/immunization/topics/malaria/vaccine_roadmap/en/)

<sup>3</sup> Duration of protection will be assessed over at least two years, with a booster dose required at most once during the two year period.

- 
- Roadmap strategic goal 2: Malaria vaccines that reduce transmission of the parasite and thereby substantially reduce the incidence of human malaria infection. This will enable elimination in multiple settings. Vaccines to reduce transmission should be suitable for administration in mass campaigns.

This guidance presents PPCs that correspond to these goals.

Any malaria vaccine that becomes licensed and potentially available will undergo evidence-based assessment for policy recommendations by the Strategic Advisory Group of Experts (SAGE) on Immunisation and the Malaria Policy Advisory Committee (MPAC).

### 1.3 Context of available WHO recommended malaria interventions

Malaria vaccines will be tested and deployed in conjunction with other WHO recommended malaria control measures. These include effective artemisinin combination anti-malarial chemotherapy, use of quality-assured rapid diagnostic tests, long-lasting insecticide-treated bednets and other vector control measures, including indoor residual spraying with insecticide. In addition drug-based prophylaxis is recommended by WHO in certain settings and target groups. In the future, the recommended malaria control measures may also include a first-generation malaria vaccine.

Even if a first-generation malaria vaccine becomes available, it seems likely that the efficacy and duration of protection will be modest and there will remain a pressing need to develop second generation vaccines with higher efficacy to further reduce malaria cases and deaths. Furthermore, control measures are increasingly threatened by the development of resistance to drugs and insecticides, and so authorities in most malaria-endemic countries will view a safe and highly effective second generation malaria vaccine as a high priority for possible introduction.

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_27606](https://www.yunbaogao.cn/report/index/report?reportId=5_27606)

